Evidence map›Paper›PMID 36992418›Full record

ArticleViruses2023

T Cell Responses Correlate with Self-Reported Disease Severity and Neutralizing Antibody Responses Predict Protection against SARS-CoV-2 Breakthrough Infection.

Zhen Zhao, Attila Kumanovics, Tanzy Love, Stacy E F Melanson, Qing H Meng, Alan H B Wu, Joesph Wiencek, Fred S Apple, Caitlin R Ondracek, David D Koch and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. COVID-19 vaccines: Immune correlates and clinical outcomes.Human vaccines & immunotherapeutics · 2024
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zhen ZhaoDepartment of Laboratory Medicine and Pathology, Weill Cornell Medicine, New York, NY 10065, USA.
Attila KumanovicsDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
Tanzy LoveDepartment of Biostatistics and Computational Biology, University of Rochester, Rochester, NY 14642, USA.ORCID 0000-0002-7154-0229
Stacy E F MelansonDepartment of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
Qing H MengDepartment of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Alan H B WuDepartment of Laboratory Medicine, University of California, San Francisco, CA 94143, USA.
Joesph WiencekDepartment of Pathology, Microbiology and Immunology, Vanderbilt School of Medicine, Nashville, TN 37240, USA.ORCID 0000-0001-9595-6299
Fred S AppleDepartment of Laboratory Medicine and Pathology, Hennepin Healthcare/Hennepin County Medical Center, Minneapolis, MN 55415, USA.
Caitlin R OndracekAmerican Association for Clinical Chemistry, Washington, DC 22203, USA.ORCID 0000-0003-4529-659X
David D KochDepartment of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30303, USA.
Robert H ChristensonDepartment of Pathology, University of Maryland School of Medicine, 685 W. Baltimore Street, Baltimore, MD 21201, USA.
Yan Victoria ZhangDepartment of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 626, Rochester, NY 14642, USA.

Funding

VISUAL INDICES OF NEUROTOXICITYP30ES001247 · NIEHS · UNIVERSITY OF ROCHESTER · PI Martha Susiarjo · 1985 to 2026
$42.8M
NIEHS NIH HHS P30 ES001247
6 · The paper itself

Abstract

objectivesThe objective of this prospective study was to investigate the role of adaptive immunity in response to SARS-CoV-2 vaccines. DESIGN AND

methodsA cohort of 677 vaccinated individuals participated in a comprehensive survey of their vaccination status and associated side effects, and donated blood to evaluate their adaptive immune responses by neutralizing antibody (NAb) and T cell responses. The cohort then completed a follow-up survey to investigate the occurrence of breakthrough infections.

resultsNAb levels were the highest in participants vaccinated with Moderna, followed by Pfizer and Johnson & Johnson. NAb levels decreased with time after vaccination with Pfizer and Johnson & Johnson. T cell responses showed no significant difference among the different vaccines and remained stable up to 10 months after the study period for all vaccine types. In multivariate analyses, NAb responses (<95 U/mL) predicted breakthrough infection, whereas previous infection, the type of vaccine, and T cell responses did not. T cell responses to viral epitopes (<0.120 IU/mL) showed a significant association with the self-reported severity of COVID-19 disease.

conclusionThis study provides evidence that NAb responses to SARS-CoV-2 vaccination correlate with protection against infection, whereas the T cell memory responses may contribute to protection against severe disease but not against infection.

Indexed as

COVID-19COVID-19 VaccinesAntibodies, NeutralizingAntibodies, ViralBreakthrough InfectionsHumansPatient AcuityProspective StudiesSARS-CoV-2Self ReportVaccinationAntibodies, NeutralizingAntibodies, ViralCOVID-19 Vaccinesbreakthrough infectionCOVID-19neutralizing antibodySARS-CoV-2T cell responsevaccine

Identifiers

PMID36992418
PMCPMC10058409

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.